Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

28. März 2025 19:40 ET | Quelle: Curium US LLC

Curium เสร็จสิ้นการเข้าซื้อ Monrol ซึ่งเป็นส่วนหนึ่งของแผนการขยายกำลังการผลิต Lutetium-177 และฐานการผลิต PET อย่างมีนัยสำคัญ

วางตำแหน่ง Curium เป็นผู้ผลิตไอโซโทป Lu-177 ชั้นนำนำความเชี่ยวชาญด้านการวิจัยและพัฒนาที่เป็นนวัตกรรมและลำดับขั้นตอนการทำงานมาสู่ Curiumเพิ่มความครอบคลุมทางภูมิศาสตร์และห่วงโซ่อุปทาน SPECT & PET...
28. März 2025 19:40 ET | Quelle: Curium US LLC

Curium completa la adquisición de Monrol como parte de su plan para expandir significativamente la capacidad de lutecio-177 y presencia PET

Posiciona a Curium como fabricante líder de isótopo Lu-177Aporta experiencia innovadora en I+D y una línea de desarrollo de productos a CuriumMejora la cobertura geográfica y la cadena de suministro...
28. März 2025 19:40 ET | Quelle: Curium US LLC

Curium Menyelesaikan Akuisisi Monrol sebagai Bagian dari Rencananya untuk Secara Signifikan Meningkatkan Kapasitas Lutetium-177 dan Jaringan PET

Menempatkan Curium sebagai produsen terkemuka isotop Lu-177Memberikan keahlian Litbang dan rangkaian tahap pengembangan produk (pipeline) yang inovatif ke CuriumMeningkatkan jangkauan geografis dan...
28. März 2025 02:00 ET | Quelle: Curium

Curium Completes the Acquisition of Monrol as Part of its Plan to Significantly Expand Lutetium-177 Capacity and PET Footprint

Positions Curium as leading manufacturer of Lu-177 isotope Brings innovative R&D expertise and pipeline to Curium
30. Januar 2025 07:22 ET | Quelle: Curium

Curium Expands European Supply of Iodine-131 Diagnostic Capsules with New Partnership Agreement with Izotop

Curium announced today that it has expanded its existing partnership with Institute of Isotopes Co. Ltd. (Izotop).
28. Januar 2025 04:24 ET | Quelle: Curium

Curium Further Expands European Availability of PYLCLARI – an Innovative 18F-PSMA PET Radiopharmaceutical Indicated in Patients with Prostate Cancer

Curium announced that in Estonia, Finland, Latvia, and Sweden, PYLCLARI® is now available for patients with prostate cancer.
19. November 2024 03:30 ET | Quelle: Curium

Curium Completes Enrollment Early of Phase 3 SOLAR-RECUR Prostate Cancer Trial

ST. LOUIS, Mo., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that it has completed enrollment of its Phase 3 SOLAR-RECUR clinical trial. The trial is a...
13. November 2024 10:57 ET | Quelle: Curium

Curium Announces ECLIPSE Trial Has Met Primary Endpoint, Demonstrating a Statistically Significant and Clinically Meaningful Benefit for Patients With PSMA-Positive Metastatic Castration Resistant Prostate Cancer

ST. LOUIS, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that its ECLIPSE trial met its primary endpoint. ECLIPSE is a pivotal Phase 3, multi-center,...
02. Oktober 2024 11:01 ET | Quelle: Curium US LLC

Curium Công bố Quan hệ Đối tác Chiến lược với PeptiDream nhằm phát triển Đồng vị phóng xạ trong Chuẩn trị ung thư tuyến tiền liệt tại Nhật Bản

Nội dung hợp tác bao gồm phát triển lâm sàng, hoàn thành hồ sơ pháp lý, và thương mại hóa các sản phẩm tại Nhật 177Lu-PSMA-I&T và 64Cu-PSMA-I&TXây dựng trên nền tảng quan hệ bên vững giữa hai...
02. Oktober 2024 11:01 ET | Quelle: Curium US LLC

Curium 宣布与 PeptiDream 达成战略合作，在日本开展前列腺癌诊疗一体化项目

此次合作将涵盖在日本开展的 177Lu-PSMA-I&T 和 64Cu-PSMA-I&T 的临床开发、监管备案及商业化进程这一合作建立在两家公司长期以来的紧密关系之上在日本，每年约有 90,000 例新诊断的前列腺癌病例巴黎, Oct. 02, 2024 (GLOBE NEWSWIRE) -- 全球核医学领域的领先企业 Curium 今日宣布与 PeptiDream...

Vorherige Seite

Nächste Seite